Immunoreactivity for LN2 and LN3 distinguishes small cell carcinomas from non-small cell carcinomas in the lung

Zhong Xue Hua, Kathryn E. Tanaka, Henry D. Tazelaar, Jeffrey Myers, Glen S. Markowitz, Alain C. Borczuk

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Immunoreactivity to LN2 and LN3, monoclonal antibodies that recognize components of the class II major histocompatibility complex, was assessed in 72 cases of non-small cell lung carcinoma (NSCLC) (32 biopsy specimens, 40 resection specimens) and 64 cases of small cell carcinoma (56 biopsy specimens, 8 resections) of the lung. All cases were reviewed independently by three pathologists for histological classification. Only 1 of the 64 small cell carcinomas showed immunoreactivity for LN2, and none of the 64 cases showed reactivity for LN3. Among the non-small cell carcinomas, 25 of 48 cases were positive for LN2 and 43 of 71 were positive for LN3; the sensitivity was greater for adenocarcinoma (78.5%) than for squamous cell carcinoma (37%). A combined sensitivity of 64.7% was observed when the results of LN2 and LN3 were combined, and this sensitivity was not significantly diminished in the biopsy subset of cases (59.4%). Differentiation within histological subtypes of NSCLC (ie, well, moderate, or poorly differentiated) did not alter test sensitivity. In conclusion, LN2 and LN3, used alone or in combination, appear highly specific for non-small cell carcinoma and moderately sensitive in both biopsy and resection specimens; therefore, these antibodies may be diagnostically useful in distinguishing small cell from non-small cell carcinoma of the lung.

Original languageEnglish (US)
Pages (from-to)1441-1446
Number of pages6
JournalHuman Pathology
Volume29
Issue number12
StatePublished - 1998
Externally publishedYes

Fingerprint

Small Cell Carcinoma
Non-Small Cell Lung Carcinoma
Biopsy
Carcinoma
Major Histocompatibility Complex
Squamous Cell Carcinoma
Adenocarcinoma
Monoclonal Antibodies
Lung
Antibodies

Keywords

  • HLA-DR
  • LN2
  • LN3
  • Lung carcinoma
  • Neuroendocrine

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Hua, Z. X., Tanaka, K. E., Tazelaar, H. D., Myers, J., Markowitz, G. S., & Borczuk, A. C. (1998). Immunoreactivity for LN2 and LN3 distinguishes small cell carcinomas from non-small cell carcinomas in the lung. Human Pathology, 29(12), 1441-1446.

Immunoreactivity for LN2 and LN3 distinguishes small cell carcinomas from non-small cell carcinomas in the lung. / Hua, Zhong Xue; Tanaka, Kathryn E.; Tazelaar, Henry D.; Myers, Jeffrey; Markowitz, Glen S.; Borczuk, Alain C.

In: Human Pathology, Vol. 29, No. 12, 1998, p. 1441-1446.

Research output: Contribution to journalArticle

Hua, ZX, Tanaka, KE, Tazelaar, HD, Myers, J, Markowitz, GS & Borczuk, AC 1998, 'Immunoreactivity for LN2 and LN3 distinguishes small cell carcinomas from non-small cell carcinomas in the lung', Human Pathology, vol. 29, no. 12, pp. 1441-1446.
Hua ZX, Tanaka KE, Tazelaar HD, Myers J, Markowitz GS, Borczuk AC. Immunoreactivity for LN2 and LN3 distinguishes small cell carcinomas from non-small cell carcinomas in the lung. Human Pathology. 1998;29(12):1441-1446.
Hua, Zhong Xue ; Tanaka, Kathryn E. ; Tazelaar, Henry D. ; Myers, Jeffrey ; Markowitz, Glen S. ; Borczuk, Alain C. / Immunoreactivity for LN2 and LN3 distinguishes small cell carcinomas from non-small cell carcinomas in the lung. In: Human Pathology. 1998 ; Vol. 29, No. 12. pp. 1441-1446.
@article{dc0959c606b6409b9db84416c96ce35a,
title = "Immunoreactivity for LN2 and LN3 distinguishes small cell carcinomas from non-small cell carcinomas in the lung",
abstract = "Immunoreactivity to LN2 and LN3, monoclonal antibodies that recognize components of the class II major histocompatibility complex, was assessed in 72 cases of non-small cell lung carcinoma (NSCLC) (32 biopsy specimens, 40 resection specimens) and 64 cases of small cell carcinoma (56 biopsy specimens, 8 resections) of the lung. All cases were reviewed independently by three pathologists for histological classification. Only 1 of the 64 small cell carcinomas showed immunoreactivity for LN2, and none of the 64 cases showed reactivity for LN3. Among the non-small cell carcinomas, 25 of 48 cases were positive for LN2 and 43 of 71 were positive for LN3; the sensitivity was greater for adenocarcinoma (78.5{\%}) than for squamous cell carcinoma (37{\%}). A combined sensitivity of 64.7{\%} was observed when the results of LN2 and LN3 were combined, and this sensitivity was not significantly diminished in the biopsy subset of cases (59.4{\%}). Differentiation within histological subtypes of NSCLC (ie, well, moderate, or poorly differentiated) did not alter test sensitivity. In conclusion, LN2 and LN3, used alone or in combination, appear highly specific for non-small cell carcinoma and moderately sensitive in both biopsy and resection specimens; therefore, these antibodies may be diagnostically useful in distinguishing small cell from non-small cell carcinoma of the lung.",
keywords = "HLA-DR, LN2, LN3, Lung carcinoma, Neuroendocrine",
author = "Hua, {Zhong Xue} and Tanaka, {Kathryn E.} and Tazelaar, {Henry D.} and Jeffrey Myers and Markowitz, {Glen S.} and Borczuk, {Alain C.}",
year = "1998",
language = "English (US)",
volume = "29",
pages = "1441--1446",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "12",

}

TY - JOUR

T1 - Immunoreactivity for LN2 and LN3 distinguishes small cell carcinomas from non-small cell carcinomas in the lung

AU - Hua, Zhong Xue

AU - Tanaka, Kathryn E.

AU - Tazelaar, Henry D.

AU - Myers, Jeffrey

AU - Markowitz, Glen S.

AU - Borczuk, Alain C.

PY - 1998

Y1 - 1998

N2 - Immunoreactivity to LN2 and LN3, monoclonal antibodies that recognize components of the class II major histocompatibility complex, was assessed in 72 cases of non-small cell lung carcinoma (NSCLC) (32 biopsy specimens, 40 resection specimens) and 64 cases of small cell carcinoma (56 biopsy specimens, 8 resections) of the lung. All cases were reviewed independently by three pathologists for histological classification. Only 1 of the 64 small cell carcinomas showed immunoreactivity for LN2, and none of the 64 cases showed reactivity for LN3. Among the non-small cell carcinomas, 25 of 48 cases were positive for LN2 and 43 of 71 were positive for LN3; the sensitivity was greater for adenocarcinoma (78.5%) than for squamous cell carcinoma (37%). A combined sensitivity of 64.7% was observed when the results of LN2 and LN3 were combined, and this sensitivity was not significantly diminished in the biopsy subset of cases (59.4%). Differentiation within histological subtypes of NSCLC (ie, well, moderate, or poorly differentiated) did not alter test sensitivity. In conclusion, LN2 and LN3, used alone or in combination, appear highly specific for non-small cell carcinoma and moderately sensitive in both biopsy and resection specimens; therefore, these antibodies may be diagnostically useful in distinguishing small cell from non-small cell carcinoma of the lung.

AB - Immunoreactivity to LN2 and LN3, monoclonal antibodies that recognize components of the class II major histocompatibility complex, was assessed in 72 cases of non-small cell lung carcinoma (NSCLC) (32 biopsy specimens, 40 resection specimens) and 64 cases of small cell carcinoma (56 biopsy specimens, 8 resections) of the lung. All cases were reviewed independently by three pathologists for histological classification. Only 1 of the 64 small cell carcinomas showed immunoreactivity for LN2, and none of the 64 cases showed reactivity for LN3. Among the non-small cell carcinomas, 25 of 48 cases were positive for LN2 and 43 of 71 were positive for LN3; the sensitivity was greater for adenocarcinoma (78.5%) than for squamous cell carcinoma (37%). A combined sensitivity of 64.7% was observed when the results of LN2 and LN3 were combined, and this sensitivity was not significantly diminished in the biopsy subset of cases (59.4%). Differentiation within histological subtypes of NSCLC (ie, well, moderate, or poorly differentiated) did not alter test sensitivity. In conclusion, LN2 and LN3, used alone or in combination, appear highly specific for non-small cell carcinoma and moderately sensitive in both biopsy and resection specimens; therefore, these antibodies may be diagnostically useful in distinguishing small cell from non-small cell carcinoma of the lung.

KW - HLA-DR

KW - LN2

KW - LN3

KW - Lung carcinoma

KW - Neuroendocrine

UR - http://www.scopus.com/inward/record.url?scp=0031675867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031675867&partnerID=8YFLogxK

M3 - Article

C2 - 9865830

AN - SCOPUS:0031675867

VL - 29

SP - 1441

EP - 1446

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 12

ER -